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In view of the high imminent risk of having subsequent fractures
after a fracture, early evaluation and treatment decisions to pre-
vent subsequent fractures are advocated. After a hip fracture, the
fracture liaison service (FLS) and orthogeriatric care are considered
the most appropriate organisational approaches for secondary
fracture prevention following a recent fracture.
Their introduction and implementation have been shown to in-
crease evaluation and treatment of patients at high risk for sub-
sequent fracture. Of real-world cohort studies, most, but not all
studies, indicate a lower incidence of fracture and longer survival
after treatment with nitrogen-containing bisphosphonates.
© 2019 Elsevier Ltd. All rights reserved.At the age of 50 years, 50% of women and 25% of men will sustain a fracture during the remaining
lifetime [1]. Subsequent fractures contribute substantially to this overall fracture burden. Of all low-
trauma fractures after the age of 40 years, 40% of fractures in women and 24% in men are subse-
quent fractures [2]. Nearly all fractures are associated with an increased risk for future fracture,
regardless of age, baseline bone mineral density (BMD) and fracture location [3e5]. Furthermore, mostl Medicine, Subdivision Rheumatology, CAPHRI Care and Public Health
entre þ, P.O. Box 5800, 6202 AZ Maastricht, the Netherlands.
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P. Geusens et al. / Best Practice & Research Clinical Rheumatology 33 (2019) 278e289 279subsequent fractures occur within the first years after a fracture, which is refereed as the ‘imminent
fracture risk’, i.e. the risk of having subsequent fracture is higher in short term than in long term after a
fracture [6].
To prevent subsequent fractures, patients with a recent fracture are, therefore, in need of adequate
evaluation and treatment decisions shortly after the initial fracture. However, there is still a large gap in
the number of patients with a recent fracture who are actually evaluated and treated [7e9]. In this
context, the American Society of Bone and Mineral Research (ASBMR), the International Osteoporosis
Foundation (IOF) and the European League against Rheumatism (EULAR) together with the European
Federation of National Associations of Orthopaedics and Traumatology (EFORT) have formulated rec-
ommendations for secondary fracture prevention [10e12].
The FLS is considered the most effective organisational structure to increase evaluation and
treatment after any fracture [13] and orthogeriatric care in frail elderly after hip fracture (meta-analysis
and randomised control trial (RCT))[13].The four pillars of an FLS
Building up an FLS requires four pillars (Fig. 1). The first pillar consists of a bone leader, a coordi-
nator, a multidisciplinary team and a business plan to run an FLS [10e12,14,15]. The bone leader is a
specialist in metabolic bone diseases who takes care of the organisation of a multidisciplinary team in
consultation with the orthopaedic surgeons. The coordinator, often a well-educated nurse, is
responsible for organising the diagnostic investigations and to help starting interventions and
providing adequate medical information to patients and general practitioners (GPs) [10e12,16,17].
The second pillar consists of the identification of all patients with a recent fracture and the selection
of patients for invitation to the FLS [10e12]. Selected patients have to be educated, contacted and
invited [13,18]. This can be performed at the emergency department, at the plaster consultation, in the
hospital when patients are hospitalised, at the orthogeriatric care unit and at post-treatment stage






and invita on of
fracture pa ents







Evalua on and treatment
Fig. 1. The four pillars of an FLS.
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treatment initiation [13,19].
A third pillar consists of orthogeriatric care, which focuses on patients with a recent hip fracture.
Orthogeriatric services are designed to provide specialist geriatric care to the frail older trauma patient
and are integral tomultidisciplinarymanagement following admission preoperatively, peri-operatively
and post-operatively. The components include rapid optimisation of fitness for surgery, early identi-
fication of rehabilitation goals to facilitate return to pre-fracture residence and long-term well-being,
as appropriate, and integrating with related services within secondary care and the community,
including secondary fracture prevention. The development of orthogeriatrician-led FLS models focuses
mainly on patients with hip fractures but could also be a model for admitted frail elderly with a recent
major fracture, whereas ambulatory patients with non-vertebral fractures (NVFs) and vertebral frac-
tures (VFs) are preferably managed in an outpatient FLS setting [20e22].
The fourth pillar is communication with the GP and organisation of adequate follow up.
Reasons for evaluation and treatment gap after a fracture
Currently, there is a substantial treatment gap for osteoporosis in general, which is highly variable
throughoutEurope, i.e. between25%and95%[8,23,24].Variousreasonshavebeendocumented for thisgap.
Most patients perceive their risk for future fractures as low [25], also patients with comorbidities
such as neurologic, rheumatologic, respiratory and gastro-intestinal comorbidities [26]. Even patients
with postmenopausal osteoporosis perceive fractures as random events, related to hazards in the
environment such as accidental falls or unsafe behaviour [27]. Patients referred for bone densitometry
accept considerably higher fracture risk than doctors to justify drug treatment [28] and have difficulties
understanding the concept of 10 year risk [27,29]. On the other hand, post-fracture osteoporosis
medication use was higher in women than in men, in patients with previously diagnosed osteoporosis
and in those who had a BMD assessment before the fracture [30].
Patients, the lay press, the medical literature and doctors, especially those treating tooth problems,
have - sometimes excessive - concerns about side effects such as atypical femoral fractures (AFFs) and
osteonecrosis of the jaw [31e33]. Other reasons for the evaluation and treatment gap are older age,
residing in long-term care and lack of education about benefits and risks of treatment in patients, the
lay press and even GPs [8,34,35]. In addition, there may be factors that attribute to the evaluation and
treatment gap related to doctors and to local or national health organisations. Examples are the lack of
a local bone leader and fracture nurse, lack of communication between specialists and between spe-
cialists and GPs, and insufficient organisational and financial support from local or national health
organisations [10e13,15,18,36e39].
Case finding: how to organise transfer from fracture treatment to secondary fracture
prevention?
Implementation of an FLS requires arranging systematic identification of all patients who enter the
ED because of a fracture. Of the identified patients, those with following criteria need to be selected:
>50 years old, excluding finger, toe, skull and pathologic and major traffic accident fractures. These
selected patients then need to be informed about their potential subsequent imminent and long-term
fracture risk and invited to attend the FLS for counselling, evaluation and treatment according to
personalised precision medicine.
Many attempts have been undertaken to organise the transfer of patients with a recent fracture
after acute fracture care towards secondary fracture prevention [13,18].
Examples are education of patients with a recent fracture and alerting the GP by a discharge letter.
However, such approach is less effective than an FLS [13].
Which patients should be selected for evaluation at the FLS?
Apart from orthopaedic descriptions of fractures (comminute, transverse, oblique etc.), there are
many definitions in the literature for characterising the complex nature of a fracture (Fig. 2) [40e42].
comminute, transverse, oblique etc.
vertebral, non-vertebral, hip, non-vertebral non-hip, total 
fractures, any clinical, around joints (shoulder, wrist)
‘clinical’, ‘sub-clinical’, ‘radiographic’, ‘new vertebral’, 
‘worsening vertebral’, ‘vertebral deformity’, 
‘imminent fracture’
‘osteoporo c’, ‘osteoporosis-related’, ‘fragility’, ‘minor’, 
‘major’, ‘severe’
‘fall-related’, ‘atrauma c’, ‘non-trauma c’, ‘minimal-
trauma’, ‘low-trauma’, ‘low-energy trauma’, 
‘low-trauma osteoporo c’, ‘severe low-trauma’ or ‘major 
osteoporo c’ fractures and ‘clinical diagnosed osteoporosis’
Fig. 2. Clouded Babylonian confusion about fracture denominations (after Brueghel).
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with a fracture.
These variable fracture descriptions sometimes result in Babylonian confusion between clinicians
regarding which patient with the above-described definitions to evaluate and treat in the context of
the FLS. There is general consensus to invite following patients at the FLS:
 Women and men, 50 years or older, with a recent fracture
 All fracture locations (except fingers, toes, face and skull), and more specifically:
 Low trauma fractures, defined as fractures sustained due to fall(s) from standing height or lesser
height and by extension of other low traumas (see above)
 Patients who sustain a moderate-to high-trauma fracture are also at increased risk of having sub-
sequent fracture and could warrant inclusion (except after a major traffic accident) [3,15,43].Which patients attend the FLS?
Although VFs are the most common incident fractures after the age of 50 years in women and men
[1], most patients who are visiting the Emergency Department present with an NVF [15]. Most VFs are
not recognised because they occur sub-clinically, without typical clinical signs and symptoms of an
acute fracture [44,45], and because imaging of the spine is not performed in many patients with acute
back pain [46]. In addition, VFs may not even be diagnosed when spine images are available [47], and,
when diagnosed, they are often not treated or treated ambulatory [48].
In a recent overview, it was reported that FLSs varied in terms of patient identification, selection and
FLS attendance [49]. Patient identification and selection differed markedly among FLSs, in terms of
proportions of inpatients and outpatients, age, inclusion of women and/or men and fracture selection
(any fracture or only patients with a NVF). Exclusion criteria for FLS invitation also differed, such as
high-energy trauma fractures, pathological fractures and cognitive impairment. In addition, 20e89% of
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FLSs contains a high variability in FLS patient characteristics, such as mean age (64e80 years), pro-
portion of men (13e30%) and fracture locations (2e51% hip, <1e41% vertebral and 49e95% non-hip,
NVFs) [49].
In a national patient-level audit of the quality of FLSs in the UK, 18,356 patients were enrolled from
38 FLSs. It was concluded that national coverage of secondary fracture prevention using FLSs is still low
with variability in quality between existing FLSs [50]. Although completeness of submitted data varied,
there was also marked variability in the proportion of patients meeting recognised standards of care in
the identification of fragility fracture patient, timely initial contact and subsequent risk assessment,
and treatment initiation and monitoring [50].
In the Netherlands, where most of the hospitals run an FLS, in a study of 24,468 patients, those
attending the FLS were evaluated, treated and followed in high compliancy with the local guidelines
and with IOF standards [51]. However, the major shortcoming in FLS care was that patients invited to
attend the FLSs showed a low attendance rate of approximately 50%. The Kaiser Permanente Healthy
Bones Program is yet another programme developed for fracture prevention [52]. Data gathered by the
Capture the Fracture initiative of the IOF are available. It shows that currently >300 FLSs received a gold
status worldwide [53].Fracture risk evaluation
The aim of fracture risk evaluation after a recent fracture is, first, to identify the presence and extent
of risk factors of having subsequent fracture risk and, second, initiate appropriate treatment according
to the patient's risk.
Meanwhile, many risk factors for imminent subsequent fracture risk have been identified [6]
(Table 1).
Clinical risk factors are included in fracture risk assessment tools such as FRAX [54], Garvan [55] and
QFracture [56]. FRAX is developed at the University of Sheffield but is until now not endorsed by the
WHO [54]. Although FRAX has been internationally validated at the population level, it underestimates
the imminent subsequent fracture risk in 65 þ patients with a recent fracture [57]. In a recent analysis
of the Iceland population by the developers of FRAX, it was reported that in many cases after a recent
fracture, the 10 year fracture probability for MOFs as calculated with FRAX underestimated the real
imminent fracture risk by more than two-fold. Hazard ratio's ranged between 2.6 and 9.1, depending
on the site of fracture, age and sex [58]. The FRAX-BMI scores were below the Canadian threshold forTable 1
Risk factors for imminent subsequent fracture risk (adapted from Roux et al.) [6].
Characteristics of sentinel fracture:
Location: higher risk after major fracture than after minor fracture





Number of prior clinical fractures
Combination of low BMD with baseline presence, severity and number of VFs
Comorbidities
Increased risk of falls during rehabilitation and follow up after fracture because of walking aids and plastering, and impaired
coordination
Starting high dose of glucocorticoids
Lower walking speed, poor cognitive function, use of arms for chair stands or poor/very poor tandem stand, Parkinson's
disease, stroke and smoking
Starting high dose of glucocorticoids
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patients with recurrent fragility fracture. One reason could be that FRAX does not specifically include
the risk of falls [57,59]. The predictive potential of Garvan and QFracture algorithms, which include fall
risks, has not been documented after a recent fracture.
These clinical risk factors occur at the background of other risks, such as low bodymass index (BMI),
lifestyle (smoking and alcohol) and family history of fractures [60e65].
Subsequent fracture risk is associated with low BMD at the hip, independent of age [66]. Measuring
BMD after a recent fracture, therefore, contributes to fracture risk evaluation and specifies that the
fracture in the patient is indeed ‘osteoporotic’. In frail elderly with a hip fracture, DXA assessment will
often be difficult to perform because of low health status, frailty, low mobility and referral to other
locations such as a revalidation unit or rest home.
Half of the recurrent fractures occurred in patients with osteopenia, and subsequent fracture risk for
low trauma fractures was highest in those who had a prevalent VF [2]. Sub-clinical VFs are frequently
present in patients with a recent NVF [67,68]. Systematic guideline implementation resulted in a
significant increase in imaging of the spine by DXA and diagnosis of VFs in patients visiting the FLS with
an NVF in both genders, at any age, non-VF location and BMD [68]. Therefore, in many patients with a
presumably first NVF, this fracture is, in fact, already a second fracture. In addition, evaluating the
presence, number and severity of a VF by X-Ray or DXA contributes to identify patients at high risk of
subsequent fractures, independent of BMD [69e71].
A history of fall during the last year is associatedwith a subsequent fracture, independent of a recent
severe low-trauma fracture [72]. Many fall risk factors are related to an imminent fracture risk [73].
Therefore, fall risk evaluation by verifying the history of recent falls andmedications and comorbidities
that increase fracture risk contributes to fracture risk evaluation [72e74].
In the above cited overview of FLSs, there is a still high variability in the percentage of patients with
osteoporosis (12e54%), prevalent VFs (20e57%) and fall-related risk factors (60e84%) [49].Secondary osteoporosis and metabolic bone disorders
Many conditions, diseases and medications have been shown to increase the risk of fractures
[75]. Not surprisingly, many patients visiting the FLS report such diseases and medications in their
medical history [76,77]. Approximately 23% reported a history of previously diagnosed diseases
associated with increased fracture risk. However, metabolic bone disorders can be present sub-
clinically and were diagnosed in 27% using a standard laboratory examination [77]. These sub-
clinical newly diagnosed disorders, including low calcium intake and vitamin D deficiency, were
found in both sexes, at all ages, after all fractures and at any level of BMD. Therefore, in addition to
medical history, clinical examination and checking calcium intake and potential risks for vitamin D
deficiency, a limited laboratory investigation is also recommended in all patients with a recent
fracture. In the study of Bours et al. [77], these included serum calcium, albumin, phosphate,
creatinine, TSH, alkaline phosphatase and ESR. Other tests can be performed when indicated, e.g.
protein electrophoresis, testosterone in men less than 70 years old, 25 (OH)D, PTH, tissue trans-
glutaminase and anti-gliadin antibodies, 24-h urine collection (calcium, creatinine, sodium and
phosphate), etc.
In the above-mentioned overview of 33 FLSs, 64% performed laboratory tests [49]. There was a high
variability of newly diagnosed contributors to secondary osteoporosis and other metabolic bone dis-
orders (3e70%) [49].Initiating and follow up of treatment
Fractures should be managed in a multidisciplinary approach. Immediate treatment of the fracture
led by a trauma or orthopaedic surgeon is needed, and in case of hospital admission, supportive care
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geriatrician [21].
As the FLS is considered the most effective organisation for evaluation and treatment initiation
of secondary fracture prevention, an FLS visit is indicated for patients aged 50 years and over
with a recent fracture. Treatment is preferably initiated by the supervising clinician at the FLS
who is usually a rheumatologist, endocrinologist, internist or geriatrician, depending on the local
situation, in collaborations with trauma or orthopaedic surgeons who are providing acute
fracture care.
Organisation of FLS care for both inpatients and outpatients, including follow-up, is usually pro-
vided by a specialised FLS coordinator, usually an advanced practice provider [18,78].
Effect of FLS on evaluation, treatment initiation, subsequent fractures and mortality: is FLS
cost-effective?
Evaluation
Implementation of a structured FLS resulted in increased patient contacts and education and
increased risk evaluation by DXA, by X-ray or DXA for imaging of the spine and by laboratory inves-
tigation [10e12,68,79e83]. In contrast, there was no change in exposure to drugs that are known to
increase fracture risk [74].
Therapy initiation
Implementation of a structured FLS resulted in increased therapy initiation [13,14]. In hip fracture
patients, FLS improved non-pharmacologic measures but not the use of osteoporosis medication [84].
Factors associated with post-fracture treatment included osteoporosis medication use before
fragility fracture, higher daily calcium intake, diagnosis of osteoporosis, Asian or Pacific Islander race/
ethnicity (compared withWhite/Caucasian), higher income and hormone therapy use (past or present)
[12,85,86].
A reduced likelihood of osteoporosis medication use after a fracture included black race, higher
Charlson Comorbidity Index scores, presence of dementia, kidney diseases, high BMI, current smoking
and history of arthritis [86,87].
Effect on subsequent fractures
In a literature search of 22 reports of FLSs, only five FLS studies with heterogeneous study designs
were available, which reported on subsequent fracture rate, and three of them reported a lower
subsequent fracture rate related to FLS care when comparing fracture rates before and after the
introduction of an FLS or when comparing hospitals with and without an FLS [88].
Using an interrupted time series analysis among hip fracture patients, publication of NICE
guidance and availability of generic alendronic acid in the UK was associated with increased
prescribing and a significant contemporary decline in subsequent major and hip fractures during
three years [89]. In contrast, no reduction over two years in second hip fractures was found after
introduction of FLS care [20], possibly because of low treatment adherence [20,89]. Brozek et al.
found an increased subsequent fracture rate in bisphosphonate users after fracture, which they
related not only to longer survival but also to the presence of more comorbidities in bisphosph-
onate users [90].
In a prospective cohort study during eight years of the Glasgow FLS in 5011 women and men, all
patients received adequate calcium and vitamin D, and those at high re-fracture risk were also rec-
ommended bisphosphonates (n ¼ 2534) [91]. After adjusting for baseline differences in age, sex and
baseline fracture location, those recommended bisphosphonate treatment had a substantially lower
risk for subsequent fragility fracture and mortality.
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Orthogeriatric care and FLS decreasedmortality within 30 days andwithin one year in patients with
a hip fracture [20,21,92]. In accordance with the reduced mortality with zoledronate after hip fracture
[93], Brozek et al. [90] and Beaupre et al. [94] also reported a lower mortality in hip fracture patients
treated with oral bisphosphonates. They also found an increased re-fracture rate, which they related
not only to longer survival but also to more comorbidities in BP users [90]. In the above-mentioned
long term of the Glasgow FLS, longer survival was also found in those treated for underlying osteo-
porosis [91].Cost effectiveness of FLS
There is emerging literature about the cost effectiveness of FLS care [95], using health economic
models for the evaluation of preventing fractures. Modelling techniques include simple decision trees,
deterministic Markov processes and individual patient simulation models taking into account uncer-
tainty in multiple parameters [95]. Economic evaluation can inform decision makers on the cost-
effectiveness of the various interventions and can be the basis for the allocation of scarce health-
care resources [96].
Using Markov models based on epidemiological data and results from RCTs on fracture incidence
and prevention, models analysing the effect of treatment on secondary fracture prevention have been
statistically shown to be cost-effective after a fragility fracture in preventing second osteoporotic
fractures during a mean of six years follow-up [97] or in preventing second hip, wrist and humerus
fractures during a mean of eight years follow-up [16].
During a mean follow up of 2.6 years, Leal et al. reported that introduction and/or expansion of
Orthogeriatric and nurse-led FLS in patients with a recent hip fracture was more effective and cost-
effective than usual care, irrespective of age, sex and Charlson Comorbidity Index score [92].
However, when they incorporated the time to second hip fracture and death and the short- and
long-term costs associated with patients with hip fracture, it was not cost-saving, presumably
because longer survival could increase costs and re-fractures [92]. Considerable uncertainty
remained concerning which of the models of care should be preferred [21,92]. RCTs have been
conducted for the comparison of teriparatide with risedronate and romosozumab with alendro-
nate [98,99]. In patients with VFs and a T-score < -1.5, teriparatide was superior to risedronate in
preventing vertebral and clinical fractures. Pre-specified sub-group analyses indicated that this
superior effect of teriparatide was consistent in a wide range of patients settings, including
treatment naïve or previously treated patients, with or without a recent clinival VF or history of
NVF and at any age or BMD [100]. In a similar high-risk population, including patients with a
history of proximal femur fracture 3e24 months before randomisation, one year romosozumab
followed by two years alendronate was superior to three years alendronate in the reduction of the
risk of VFs, clinical fractures, NVFs and hip fracture [99]. Because of the higher cost of bone forming
agents, direct cost/effectiveness comparisons with anti-resorptive therapy could contribute to
select patients in whom bone forming agents can be started based on the level of subsequent
fracture risk in daily practice.
Summary
The introduction and implementation of an FLS (and orthogeriatric care after hip fracture) have
been shown to increase evaluation and treatment of patients at high risk of having subsequent fracture.
There are emerging data that this approach decreases fracture and mortality risk, although longer
survival could decrease the effect on fracture risk. Further research will be necessary to study the cost
effectiveness of FLS care, based on real-world data and Markov models.
Practice points
In view of the high imminent risk for subsequent fractures after a fracture, the fracture liaison
service (FLS) (and orthogeriatric care after hip fracture) is considered the most appropriate
organisational approach for secondary fracture prevention following a recent fracture.
Secondary fracture prevention after a recent fracture consists of four pillars:
1/ the logistics of an FLS for organising diagnostic evaluation and treatment decisions;
2/ orthogeriatric care after hip fracture;
3/ identification and invitation of patients with a recent fracture; and
4/ organising adequate follow up.
Research agenda
How to decrease the evaluation and treatment gap for secondary fracture prevention after a
recent fracture?
How to improve adherence to therapy?
What is the cost/effectiveness of FLS and orthogeriatric care?
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